SIGA starts phase 1 study of SIGA-246 for smallpox

By Lisa Kerner

Erie, Pa., Mary 2 - SIGA Technologies, Inc.'s lead drug candidate for smallpox, SIGA-246, has begun phase 1 human clinical trials examining the drug's safety and pharmacokinetics. The company expects to collect all data from the study next month.

The double-blind, randomized, placebo-controlled, ascending single-dose phase 1 clinical trial is being performed on healthy volunteers.

SIGA-246 has demonstrated significant antiviral activity in various animal models of poxvirus disease, including the complete protection of golden ground squirrels from lethal doses of monkeypox virus, according to a company news release.

New York City-based SIGA develops novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.